This along with downregulation of FoxO and upregulation of Jak-STAT signaling may be responsible for the recently reported increased efficacy of tumor specific CD8+ effector T cells in mice treated with venetoclax daily for 14 days and even more robustly in combination with anti-PD-1/PD-L1 blockade [4]. This evidence concerns the gene CD8A and neoplasm.